We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNXP icon
126
PUT
Tonix Pharmaceuticals
TNXP
$156M
– –
0
– –
SMLR
127
DELISTED
Semler Scientific
SMLR
$1.38M 0.06%
334,038
+15,840
+5% +$73.6K
XOMA
128
DELISTED
Xoma
XOMA
$1.3M 0.06%
14,130
+5,894
+72% +$511K
ACHN
129
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$1.27M 0.05%
1,677
+535
+47% +$2.13K
CBST
130
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$1.26M 0.05%
18,086
+1,496
+9% +$102K
NWBO
131
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$1.24M 0.05%
1,841
+973
+112% +$6.19K
LUMO
132
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.22M 0.05%
+5,122
New +$1.04M
ARIA
133
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.21M 0.05%
1,896
-4,085
-68% -$28.1K
IPCI
134
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$1.2M 0.05%
+31,400
New +$1.21M
GERN icon
135
CALL
Geron
GERN
$911M
$1.17M 0.05%
+3,863
New +$8.07K
CVM.WS
136
DELISTED
Cel-Sci Corp Series S
CVM.WS
$1.17M 0.05%
4,849,000
-1,467,000
-23% -$419K
OCRX
137
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.16M 0.05%
151,358
+90,632
+149% +$722K
KYTH
138
CALL
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$1.15M 0.05%
+300
New +$10.5K
OUT icon
139
Outfront Media
OUT
$5.8B
$1.15M 0.05%
+46,941
New +$1.11M
AMRN
140
Amarin Corp
AMRN
$299M
$1.14M 0.05%
32,500
-33,581
-51% -$1.05M
RPRX
141
DELISTED
Repros Therapeutics Inc.
RPRX
$1.14M 0.05%
+65,978
New +$1.08M
EXEL icon
142
CALL
Exelixis
EXEL
$14B
$1.14M 0.05%
3,356
+1,227
+58% +$4.24K
ASPX
143
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$1.11M 0.05%
+50,000
New +$1.09M
MDGN.WS
144
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$1.11M 0.05%
830,312
+13,262
+2% +$35.4K
SSKN
145
DELISTED
Strata Skin Sciences
SSKN
$1.06M 0.05%
6,576
-873
-12% -$198K
TLPH icon
146
Talphera
TLPH
$66.4M
$1.05M 0.05%
5,145
+2,829
+122% +$567K
AVNR
147
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.05M 0.05%
1,870
-3,130
-63% -$14.4K
UTHR icon
148
PUT
United Therapeutics
UTHR
$25.8B
$1.05M 0.05%
119
-98
-45% -$9.42K
PLUR icon
149
PUT
Pluri
PLUR
$17.9M
$1.04M 0.04%
42
-78
-65% -$21.5K
CORI
150
DELISTED
Corium International, Inc.
CORI
$1.03M 0.04%
+132,722
New +$1M
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.